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Morag K. Mansley1, Jessica R. Ivy1 and Matthew A. Bailey1
1The British Heart Foundation Centre for Cardiovascular Science, The University of Edinburgh, Edinburgh, UKHypertension is known as the “silent killer,” driving the global public health burden of cardiovascular and
renal disease. Blood pressure homeostasis is intimately associated with sodium balance and the distri-
bution of sodium between ﬂuid compartments and within tissues. On a population level, most societies
consume 10 times more salt that the 0.5 g required by physiological need. This high salt intake is strongly
linked to hypertension and to the World Health Organization targeting aw30% relative reduction in mean
population salt intake to arrest the global mortality due to cardiovascular disease. But how does a
habitually high-salt diet cause blood pressure to rise? In this focused review, we discuss 2 “evolutionary
medicine” concepts, presented at the ISN Forefront Meeting “Immunomodulation of Cardio-renal
Function.” We ﬁrst examine how ancestral variants in genes that conferred a selection advantage dur-
ing early human development are now maladaptive. We then discuss the conservation of “renal” sodium
transport processes across multiple organ systems, including the brain. These systems inﬂuence sodium
appetite and can exert an often-overlooked effect on long-term blood pressure control.
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license (http://creativecommons.org/licenses/by/4.0/).H ypertension is known as the “silent killer”: itrarely causes symptoms and is the chief modiﬁ-
able risk factor driving a global health crisis of car-
diovascular and renal disease.1 Hypertension exerts a
major socioeconomic burden, costing in the United
States, for example, more than 46 billion dollars per
year to manage in terms of direct health care and
associated costs.2 At the millennium it was estimated
that 972 million adults had hypertension; a 60% in-
crease is predicted by 2025, which means that
approximately 1.5 billion adults will have hyperten-
sion within the next decade.3 To arrest this increase in
prevalence, the World Health Organization (WHO)
proposes a dual strategy of improving access to inex-
pensive and effective therapeutic agents alongside ed-
ucation to improve long-term cardiovascular health
through lifestyle changes. A key target here is an
approximately 30% relative reduction in mean popu-
lation salt intake. In most countries the average salt
(NaCl) intake is 9 to 12 g per person per day, against thespondence: Matthew Bailey, BHF Centre for Cardiovascular
ce, The Queen’s Medical Research Institute, Little France
ent, The University of Edinburgh, Edinburgh EH16 6NT, UK.
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International Reports (2016) 1, 197–203WHO recommended intake of 5 g per day.4 Although
the relationship between salt intake and cardiovascular
mortality is u-shaped, targeting salt reduction toward
the recommended daily allowance (RDA) would be
beneﬁcial5: based on the INTERSALT study, long-term
compliance would lower blood pressure and signiﬁ-
cantly reduce cardiovascular events later in life.6
How Does Salt Increase Blood Pressure?
What is the relationship between salt intake that is
habitually high and long-term blood pressure? This is
difﬁcult to gauge, as most clinical studies estimate salt
intake from measurement of 24-hour urinary sodium
excretion and recent research clearly shows that this
is not an effective index of intake.7 Nonetheless, hyper-
tension research has been strongly inﬂuenced by the
computational modeling of Guyton et al., which placed
renal function at the center of long-term blood pressure
homeostasis.8 The control of effective intravascular vol-
ume through urinary excretion of salt and water offsets
any perturbation, stabilizing blood pressure around the
individual’s set point. For example, an increase in arterial
pressure will increase renal arterial pressure and, in turn,
will cause blood ﬂow through themedullary vasa recta to
rise. This hemodynamic effect promotes the release of a
variety of paracrine factors, such as adenosine triphos-
phate (ATP) and nitric oxide, which directly inhibits197
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Figure 1. The hypertensive storm. There is strong evidence
for a dynamic interaction among hormonal (chieﬂy the
reninangiotensinaldosterone system), immune, and autonomic
nervous systems in the physiological regulation of blood pressure. In
the context of a high-salt diet, these interactions may become
maladaptive, causing hypertension. Antagonists of the RAAS are
front-line antihypertensive treatments, and device-based in-
terventions are targeting the nervous system. The World Health
Organization advocates reducing dietary sodium intake to w5 g/d.
ACEIs, angiotensin-converting enzyme inibitors; ARBs, angiotensin
receptor blockers; RAAS, reninangiotensinaldosterone system.
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Henle, and distal nephron. This vasculartubular cross-
talk underpins the pressure natriuresis response, that is,
the direct relationship between sodium excretion and
renal perfusion pressure.9 If pressure natriuresis achieves
long-term stability of blood pressure, then it follows that
hypertension can be sustained only if the renal response
to elevated blood pressure is impaired: that is, hyper-
tension is caused by renal dysfunction.10 Indeed, it is
well documented that the acute pressure natriuresis
curve is right-shifted in hypertension;more importantly,
the gradient is often blunted. How such acute “loss of
function” integrates into chronic blood pressure control
is not verywell deﬁned. Itmay initiallymanifest as loss of
the normal nocturnal dip, with blood pressure remaining
high to facilitate sodium excretion and maintain bal-
ance.11 It is also argued that the acute pressure natriuresis
mechanism is not the only—or indeed, not the most
important—mechanism of sodium and ﬂuid homeosta-
sis12: a large body of work in humans, recently
reviewed,13 ﬁnds that high salt intake can increase blood
pressure without inducing volume expansion. We also
ﬁnd this in murine models of glucocorticoid hyperten-
sion.14,15 In both situations, hypertension seems to reﬂect
increased vascular tone and/or enhanced activity of the
sympathetic nervous system rather than sodium reten-
tion and volume expansion.
It is certain that chronically elevated blood pressure
reﬂects interactions between multiple systems
(Figure 1), but this article will not discuss the relative
merits of renocentric, vasculocentric, or neurogenic
views of hypertension; rather, we focus on the evolu-
tion of hypertension, discussing emerging concepts
presented at the ISN Forefront Meeting “Immunomo-
dulation of Cardio-renal Function,” held in Shenzhen,
China. First, we examine the hypothesis that the hy-
pertension pandemic reﬂects a discord between our
ancestral genes and our current high-salt environment.
What can “Evolutionary Medicine” tell us about high
blood pressure? Second, the molecular pathways con-
trolling salt reabsorption in the kidney are expressed in
other areas important for salt balance, including the
brain. We discuss recent research showing that these
central pathways can inﬂuence salt intake and blood
pressure without altering renal function.
Ancestral Genes and the Evolution of
Hypertension
As recently reviewed,16 the processes through which
sodium balance is regulated have evolved over
millennia. The reninangiotensin system, for example,
emerged approximately 400 million years ago in the
Paleozoic era, as marine organisms moved to the land198and faced a strong selection pressure to conserve an
essential micronutrient. It is proposed that these genes
no longer ﬁt: the Ancestral-Susceptibility hypothesis
posits that hypertension, like other complex modern
conditions, is a “disease of civilization” because of a
mismatch between ancient genomes and current envi-
ronment.17 According to this theory, ancestral gene
variants that promoted efﬁcient sodium retention
accrued a selection advantage as humans ﬁrst devel-
oped in the hot and dry African savannah with sodium
chloride a scarce nutrient.18 The selection pressure
changed following the African diaspora, but the lat-
itudinal cline of heat adaptation remained a strong
driver of natural selection.19 This hypothesis20 is
broadly supported by the difference in hypertension
prevalence in populations: Individuals of white
ethnicity have a lower prevalence of salt-sensitive
hypertension than do African Americans; populations
from hot climates are more susceptible to hypertension
than those from cold climates.19 At the gene level, there
is evidence that ancestral “sodium-conserving” vari-
ants contribute to the phenotypic variability of blood
pressure. For example, variants in the AGT promotor
that increase circulating angiotensinogen encoding
gene are found at higher frequency in African pop-
ulations21; loss of function variants expected to
reduced salt avidity have risen to a higher frequency
outside of Africa.21 Similar observations have been
made for single nucleotide polymorphisms (SNPs) in
the genes encoding the a and g subunits of ENaC19Kidney International Reports (2016) 1, 197–203
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proteins.22
How should these data be interpreted? One possible
inference is that hypertension arises from a mismatch
between environment and ancestral salt-conserving
variants. Indeed, the gain-of-function variants would
impair the pressure natriuresis response, promoting
sodium retention. Indeed, such variants in angiotensi-
nogen, for example, are associated with hypertension
in the general population.23 The persistence of ancestral
variants in the molecular machinery for salt conserva-
tion becomes deleterious when the environment
changes. In our salt-saturated society, a genome aligned
with sodium avidity is maladaptive, increasing blood
pressure and cardiovascular risk.
However, to contextualize hypertension as a
misalignment of ancestrally favorable “blood pressure”
variants is too narrow a view. Recent studies suggest
that hypertension is a modern bystander effect of
selective pressure imposed to conserve other desirable
traits. For example, an ancestral variant in the APOL1
gene, which encodes apolipoprotein-L1, is observed in
higher frequency in African Americans, contributing
to higher rates of cardiovascular and renal disease.24
The disease-causing mechanism is not deﬁned, but it
is likely that the positive evolutionary selection pres-
sure on the ancestral variant reﬂects improved pro-
tection against infection by Trypanosoma brucei, which
causes sleeping sickness, rather than a beneﬁcial effect
on blood pressure homeostasis.
A similar picture is emerging for gain-of-function
variants in UMOD, the gene encoding uromodulin
(Tamm-Horsfall) protein. Common gain-of-function
SNPs in UMOD associate with hypertension,
low glomerular ﬁltration rate, and risk of renal
disease.25–28 The evolutionary genetics of 1 “risk”
SNP (rs4293393) was examined further and identiﬁed
as the ancestral allele based on expression in the
genomes of nonhuman primates.29 Further
sequencing of ancient hominid genomes identiﬁed a
protective allele, but this is now found only at low
frequency. Overall, this indicates that the evolution
of modern man placed a strong selection pressure in
favor of the ancestral, risk-associated allele, probably
because this confers protection against bacterial uri-
nary tract infection and regulates the innate immune
system.29
What does Evolutionary Medicine tell us about
hypertension? First, these studies underscore the ne-
cessity to return to a more “primitive” diet, low in
sodium and high in potassium. Second, they can pro-
vide new mechanistic insights into blood pressure
control: the study of ancestral variants is identifying
new loci associated with hypertension, includingKidney International Reports (2016) 1, 197–203kinases that regulate ENaC and sodium chloride co-
transporter (NCC).22
Salt Appetite and Blood Pressure
Early terrestrial animals evolved highly effective stra-
tegies to conserve sodium, and it is evident that both
afferent (i.e., salt taste and hunger; gastrointestinal
absorption) and efferent (i.e., renal excretion; sweat)
arms of salt homeostasis engage a conserved molecular
framework of sodium transport proteins and regulatory
kinases (Figure 2). Mutations in the genes encoding
these key proteins cause Mendelian (monogenic) blood
pressure disorders, all of which have an impact on
sodium homeostasis.30
This framework is exempliﬁed in the principal cell of
the distal nephron (Figure 3). Aldosterone is a major
regulator of sodium balance: activation of the mineral-
ocorticoid receptor stimulates sodium transport through
coordinated activation of the Na,K-ATPase in the
basolateral membrane and the epithelial sodium channel
(ENaC) in the apical membrane. This process is under-
pinned by activation of serum and glucocorticoid
induced kinase 1 (sgk1) to promote ENaC insertion and
to suppress ubiquitination and retrieval through
Nedd4-2, prolonging ENaC retention in the apical
membrane. Additional regulation is achieved by the
enzyme 11b-hydroxysteroid-dehydrogenase type 2
(11bHSD2), which converts “active” glucocorticoids
into derivatives that do not activate the mineralocorti-
coid receptor (MR).31
The same molecular machinery contributes to
sodium absorption in the GI tract, activation of salt-
taste receptors on the tongue,32 control of sodium
appetite and sympathetic drive by the brain,33–35 and
also endothelial function/peripheral vascular tone.36
Conservation of mechanisms across multiple systems
makes evolutionary sense, but how these integrate to
control blood pressure is not well deﬁned. In the rest of
this article, we focus on mineralocorticoid receptors
and the control of salt intake.
Salt appetite is often overlooked as a factor for
hypertension and, despite evidence of beneﬁt,
compliance with restricted salt intake is poor.37 This,
of course, reﬂects the abundance of salt in modern
foods, but there may also be a physiological context:
heart failure patients show increased preference for
salty foods,38 and mammals have evolved pathways in
the brain that evoke salt appetite in response to so-
dium/volume depletion.39 For example, intra-
cerebrovascular infusion of aldosterone increases
blood pressure without altering renal function in
rats.40 Similarly, intracerebrovascular infusion of
11bHSD2 inhibitors causes hypertension in rats,
without any measurable effect on whole-body sodium199
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Figure 2. Molecular mechanisms under the control of the reninangiotensinaldosterone (RAAS) system are expressed in multiple sites that
inﬂuence sodium homeostasis and blood pressure. BBB, bloodbrain barrier; CSF, cerebrospinal ﬂuid; ENaC, epithelial sodium channel;
NTS, nucleus of the solitary tract.
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MR from overactivation by glucocorticoids.31 Null
mutations in the encoding gene cause the Mendelian
syndrome of Apparent Mineralocorticoid Excess.
Hypertension in this setting is severe and considered
to be renal in origin, as the enzyme is abundantly
expressed in the distal nephron.31 Nevertheless, pa-
tients also have strong salt appetite despite suppressed
aldosterone,42 and in the general population loss-of-
function variants in HSD11B2 positively associate
with sodium intake.43 MR co-localizes with 11bHSD2
in only a few areas of the brain, populations of neu-
rons that can be considered as classical “aldosterone”
target cells.44 Several lines of evidence suggest that
these 11bHSD2-expressing neurons contribute
importantly to salt appetite and blood pressure con-
trol. In rats, 11bHSD2-expressing neurons in the nu-
cleus of the solitary tract (nucleus tractus solitarius;
NTS) are selectively activated by sodium depletion
and rapidly inactivated when salt appetite is sati-
ated.45 In mice, global genetic deletion of 11bHSD2
causes hypertension and renal sodium retention.46
Deleting the enzyme in the NTS alone does not
change blood pressure and does not impair renal200function.47 Nevertheless, these “brain knockout” mice
provide strong evidence indicating that that 11bHSD2
activity in the NTS normally exerts a signiﬁcant in-
ﬂuence on sodium homeostasis and BP control by
regulating MR activation. Deletion of the enzyme only
in the NTS uncovers an innate salt preference such
that salt intake increased 3-fold in the absence of any
overt physiological driver to consume salt. Further-
more, this increased salt intake induced hypertension:
the effect was permissive, as BP did not rise in control
mice fed the same high level of salt. This suggests that
aldosterone-sensitive neurons in the NTS normally co-
ordinate a response to increased salt intake such that
blood pressure does not rise. The mechanisms are not
yet resolved, but the knockout animals had an exag-
gerated pressor response to catecholamine and an
impaired baroreﬂex. Other studies show that
increased ENaC expression in the choroid plexus and
in neurons promotes an exaggerated pressor response
to dietary salt.34 Important here may be the homeo-
static regulation of sodium concentration in the cere-
brospinal ﬂuid: small elevations (w5 mmol/l) increase
sympathetic outﬂow, which causes hypertension by
peripheral vasoconstriction and by direct activation ofKidney International Reports (2016) 1, 197–203
Figure 3. The molecular framework for sodium transport in the principal cell of the collecting duct. Aldosterone is a regulator via the
mineralocorticoid receptor, activating transport through a network of regulatory kinases. The enzyme 11b-hydroxysteroid dehydrogenase
metabolizes cortisol to cortisone, which does not activate the mineralocorticoid receptor (MR). Glucocorticoids can activate the epithelial
sodium channel (ENaC) when in excess.
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shifting the pressure natriuresis curve to the right
and reducing the slope of the response.
It is not certain whether MR activation in the CNS is
determined by aldosterone penetrating the bloodbrain
barrier or whether aldosterone is also produced in the
brain.50 Recent evidence suggests that central synthesis
is promoted by peripheral aldosterone excess to amplify
the hypertensive response to salt.35
Dysregulation of central salt-regulating pathways
can compromise long-term adherence to restricted so-
dium intake and promote hypertension. Can these
processes be targeted to improve cardiovascular
outcome? Certainly the brain and the kidney “talk” to
each other, and bilateral renal denervation has gained
considerable traction as a device-based approach
to manage blood pressure in patients with resistant
hypertension.51,52 Interest has waned considerably
since the ﬁrst randomized, double-blinded, placebo-
controlled trial (Symplicity HNT-3) failed to reach its
primary endpoint and was halted early in 2014.53
Experimental hypertension, a setting in which effec-
tive denervation can be rigorously determined, shows
that interrupting brainkidney communication is
more effective in some models (e.g., obesity) than
others (e.g., Dahl salt-sensitive). Post hoc analysis of
Symplicity-HTN3 found beneﬁt of denervation inKidney International Reports (2016) 1, 197–203hypertensive patients with obstructive sleep apnea,54
suggesting that patient stratiﬁcation might lead to a
renaissance of this therapeutic approach.
Summary
For most of mankind’s existence, sodium chloride was a
scarce nutrient. This scarcity gave great economic value
to salt and shaped the formation and customs of our
societies, both ancient and modern. It is also reﬂected in
our DNA, encoding the multiple interlocking pathways
that efﬁciently control salt balance. However, our salt
intake is now habitually high, and these genes no longer
ﬁt: blood pressure rises, and cardiovascular disease is
the leading cause of global mortality. It is clear that BP
homeostasis is intimately associated with sodium
homeostasis and the distribution of sodium between
ﬂuid compartments and within tissues. Research has
given us a more sophisticated understanding of blood
pressure control, revealing a dynamic interplay among
hormonal, neuronal, and immune systems. Our habitu-
ally high salt intake promotes abnormal interactions and
causes hypertension. This improved understanding
may help us to develop therapeutic and lifestyle
interventions to tame the “silent killer.”
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